Rohto Pharmaceutical

4527.TPhase 2

rohto.co.jp

Rohto Pharmaceutical is a major Japanese healthcare company with a century-long history, specializing in OTC eye care, prescription pharmaceuticals, and consumer health products. Its strategic focus includes expanding its global footprint, particularly in Asia and the Americas, and advancing a pipeline of novel therapeutics in ophthalmology and dermatology. The company's strength lies in its powerful consumer brands, robust R&D capabilities in formulation technology, and a diversified business model that balances stable OTC revenue with growth from innovative prescription drugs.

Market Cap

$3.3B

Employees

3000-5000

Focus

Biotech

4527.T · Stock Price

USD 2361.50+556.50 (+30.83%)

Historical price data

AI Company Overview

Technology Platform

Specialized expertise in advanced ophthalmic and dermatological formulation technology, focusing on drug delivery systems that enhance efficacy, comfort, and user experience for topical applications.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
Mesenchymal stem cell + Placebo	Ischemic Heart Disease	Phase 2
Mesenchymal stem cell + Placebo	SARS-CoV-2 Infection( COVID-19 )	Phase 2
Mesenchymal stem cell	Decompensated Liver Cirrhosis	Phase 1/2
UDI-001	Cerebral Palsy	Phase 1/2
ADR-002K administration	D017202	Phase 1

Opportunities

Significant opportunities exist in expanding global sales of its flagship Rohto eye drop and Hada Labo skincare brands, particularly in North America and Southeast Asia.

The upcoming commercial launches of in-licensed prescription drugs (Finerenone, Etrasimod) in Japan represent major near-term revenue growth drivers in large therapeutic markets.

Risk Factors

Key risks include over-reliance on the mature Japanese market, regulatory delays for pipeline assets, intense competition in both OTC and prescription segments, and potential reputational damage from any product quality issues affecting its trusted consumer brands.

Competitive Landscape

Rohto faces competition from global OTC giants like J&J and Bausch + Lomb in eye care, and from large pharma (AbbVie, Novartis) in prescription ophthalmology/dermatology. Its differentiation stems from unparalleled brand strength in OTC eye drops in Asia, superior formulation technology for user experience, and a strategic focus on in-licensing proven therapies for the Japanese market.

Publications

Patents

Pipeline